Metabolic Syndrome and the Risk of Alzheimer’s Disease: A Meta-Analysis DOI

Yi Feng,

Lili Cheng, Weiying Zhou

et al.

Metabolic Syndrome and Related Disorders, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 19, 2024

Purpose: The relationship between metabolic syndrome (MetS) and the risk of Alzheimer's disease (AD) remains unclear. This meta-analysis aims to clarify prospective association MetS AD explore how individual components contribute this relationship.

Language: Английский

Associations Between Diabetes Mellitus and Neurodegenerative Diseases DOI Open Access

Leszek Szablewski

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 542 - 542

Published: Jan. 10, 2025

Diabetes mellitus (DM) and neurodegenerative diseases/disturbances are worldwide health problems. The most common chronic conditions diagnosed in persons 60 years older type 2 diabetes (T2DM) cognitive impairment. It was found that is a major risk for decline, dementia, Parkinson's disease (PD), Alzheimer's (AD), Huntington's (HD), amyotrophic lateral sclerosis (ALS) other disorders. Different mechanisms of associations between these diseases have been suggested. For example, it postulated an impaired intracellular insulin signaling pathway, together with hyperglycemia hyperinsulinemia, may cause pathological changes, such as dysfunction the mitochondria, oxidative stress inflammatory responses, etc. association diseases, well associations, needs further investigation. aim this review to describe mellitus, especially 1 (T1DM) selected i.e., disease, sclerosis. Suggested also described.

Language: Английский

Citations

3
Risk of Glaucoma in Non-Diabetic Patients using a Glucagon Like Peptide-1 Receptor Agonist DOI
Pranav Vasu, Emily Dorairaj, Robert N. Weinreb

et al.

Ophthalmology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

3
Understanding glucose metabolism and insulin action at the blood–brain barrier: Implications for brain health and neurodegenerative diseases DOI Creative Commons

Yiyi Zhu,

Alexei Verkhratsky, Hui Chen

et al.

Acta Physiologica, Journal Year: 2025, Volume and Issue: 241(2)

Published: Jan. 16, 2025

The blood-brain barrier (BBB) is a highly selective, semipermeable critical for maintaining brain homeostasis. BBB regulates the transport of essential nutrients, hormones, and signaling molecules between bloodstream central nervous system (CNS), while simultaneously protecting from potentially harmful substances pathogens. This selective permeability ensures that nourished shielded toxins. An exception to this are regions, such as hypothalamus circumventricular organs, which irrigated by fenestrated capillaries, allowing rapid direct response various blood components. We overview metabolic functions BBB, with an emphasis on impact altered glucose metabolism insulin in pathogenesis neurodegenerative diseases. Notably, endothelial cells constituting exhibit distinct characteristics, primarily generating ATP through aerobic glycolysis. occurs despite their exposure abundant oxygen bloodstream, typically supports oxidative phosphorylation. effects astrocytes, form glial limitans component show marked sexual dimorphism. nutrient sensing hypothalamus, along signaling, systemic metabolism. Insulin modifies regulating expression tight junction proteins, angiogenesis, vascular remodeling, well modulating flow brain. disruptions particularly evident diseases, Alzheimer's disease Parkinson's disease, where breakdown accelerates cognitive decline. review highlights role normal functionality investigates how these pathways contribute onset progression

Language: Английский

Citations

2
Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis DOI Creative Commons
Xiahao Ding, Yin Li, Lin Zhang

et al.

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(7), P. 4583 - 4593

Published: June 12, 2024

Mild cognitive impairment (MCI) heightens Alzheimer's disease (AD) risk, with diabetes mellitus (DM) potentially exacerbating this vulnerability. This study identifies the optimal intervention period and neurobiological targets in MCI to AD progression using Disease Neuroimaging Initiative dataset.

Language: Английский

Citations

14
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease DOI Creative Commons

Chien‐Tai Hong,

Jia‐Hung Chen,

Chaur‐Jong Hu

et al.

Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 31(1)

Published: Nov. 5, 2024

Abstract Neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s (PD) are common complications of diabetes, arising from insulin resistance, inflammation, other pathological processes in the central nervous system. The potential numerous antidiabetic agents to modify neurodegenerative disease progression, both preclinically clinically, has been assessed. These may provide additional therapeutic benefits beyond glycemic control. Introduced twenty-first century, glucagon-like peptide-1 receptor agonists (GLP-1RAs) a class drugs noted not only for their potent glucose-lowering effects but also cardiovascular renal protective benefits. Various GLP-1RAs have demonstrated significant vitro vivo models diseases through modulating variety pathogenic mechanisms, neuroinflammation, autophagy, mitochondrial dysfunction, abnormal phosphorylation pathognomonic proteins. substantial on cognitive behavioral functions, such as motor function. However, clinical trials investigating AD, PD, mild impairment, psychiatric disorders, diabetes yielded mixed results This review examines link between explores neurodegeneration, provides concise overview GLP-1 pathway, discusses preclinical trial outcomes cognition AD PD. proposed new strategies design future RAs

Language: Английский

Citations

11
Role of MARK2 in the nervous system and cancer DOI
Yining Lei, Ruyi Zhang, Fei Cai

et al.

Cancer Gene Therapy, Journal Year: 2024, Volume and Issue: 31(4), P. 497 - 506

Published: Feb. 2, 2024

Language: Английский

Citations

4
The potential role of gut microbiota-derived metabolites as regulators of metabolic syndrome-associated mitochondrial and endolysosomal dysfunction in Alzheimer’s disease DOI Creative Commons
Young Hyun Jung, Chang Woo Chae, Ho Jae Han

et al.

Experimental & Molecular Medicine, Journal Year: 2024, Volume and Issue: 56(8), P. 1691 - 1702

Published: Aug. 1, 2024

Although the role of gut microbiota (GMB)-derived metabolites in mitochondrial and endolysosomal dysfunction Alzheimer's disease (AD) under metabolic syndrome remains unclear, deciphering these host-metabolite interactions represents a major public health challenge. Dysfunction mitochondria networks (ELNs) plays crucial can exacerbate AD progression, highlighting need to study their reciprocal regulation for better understanding how is linked syndrome. Concurrently, disorders are associated with alterations composition GMB. Recent evidence suggests that changes GMB its may be involved pathology. This review highlights mechanisms syndrome-mediated development, focusing on interconnected roles dysfunction, ELN abnormalities, metabolites. We also discuss pathophysiological GMB-derived metabolites, including amino acids, fatty other extracellular vesicles, mediating effects dysfunction. Finally, this proposes therapeutic strategies by directly modulating functions through targeting

Language: Английский

Citations

4
Diabetes Mellitus Impairs Blood‐Brain Barrier Integrality and Microglial Reactivity DOI Open Access
Shaojun Liu,

Jie Hao,

Tingting Yu

et al.

Journal of Biophotonics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 27, 2025

ABSTRACT Diabetes mellitus (DM), a chronic metabolic disorder that adversely affects the blood–brain barrier (BBB) and microglial function in central nervous system (CNS), contributing to neuronal damage neurodegenerative diseases. However, underlying molecular mechanisms linking diabetes BBB dysfunction dysregulation remain poorly understood. Here, we assessed impacts of on reactivity investigated its mechanisms. We found severely disrupted integrity response vascular injury. also revealed potential relationship between disruption impaired function, whereby increasing permeability led downregulation P2RY12 expression, thereby impairing protection against cerebrovascular Understanding these may contribute developing therapeutic strategies for diabetes‐related neurological complications.

Language: Английский

Citations

0
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases DOI Creative Commons
Qiuxia Jiao, Yuan Huang, Jinhan He

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 238 - 238

Published: Feb. 12, 2025

Metabolic diseases like obesity and diabetes are on the rise, therapies with biomacromolecules (such as proteins, peptides, antibodies, oligonucleotides) play a crucial role in their treatment. However, these drugs traditionally injected. For patients chronic (e.g., metabolic diseases), long-term injections accompanied by inconvenience low compliance. Oral administration is preferred, but delivery of challenging due to gastrointestinal barriers. In this article, we introduce available biomacromolecule for treatment diseases. The barriers oral drug strategies overcome also explored. We then discuss alleviating defects, including glucose metabolism, lipid energy such insulin, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, fibroblast growth factor 21 analogues, peptide YY analogues.

Language: Английский

Citations

0
The Neurobiology of Comorbidities DOI
Mojtaba Oraki Kohshour,

Alba Navarro-Flores,

Monika Budde

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0